Argenx and Caribou Biosciences Shares Slide as Dow Futures Drop

Key Facts

1Dow futures fell by 450 points amid a general decline in U.S. markets.

2Argenx shares sank 8.7% after a clinical trial for Sjögren’s syndrome was halted for futility.

3Caribou Biosciences shares recorded a notable decline during Thursday's pre-market session.

Argenx shares sank 8.7% after a clinical trial for Sjögren’s syndrome was halted for futility, Benzinga reported. Dow futures fell by 450 points amid a general decline in U.S. markets, while Caribou Biosciences shares also recorded a notable decline during the pre-market session on Thursday, October 8, 2026.

CRBU closed at $0.6174 on October 7, 2026, with the session trading between a low of $0.546 and a high of $0.67. The decline in the biotech sector is driven by specific negative clinical trial news for Argenx which impacted investor sentiment alongside a broader market sell-off.